PMID- 24828014
OWN - NLM
STAT- MEDLINE
DCOM- 20150720
LR  - 20211021
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 24
IP  - 10
DP  - 2014 Dec
TI  - Change in plasma cytokine levels during risperidone treatment in children with 
      autism.
PG  - 586-9
LID - 10.1089/cap.2013.0108 [doi]
AB  - BACKGROUND: Atypical antipsychotics decrease irritability in autism. They also 
      affect the cytokine network. Psychological stress, depression, and, possibly, 
      autism spectrum disorder (ASD) are associated with the production of 
      pro-inflammatory cytokines. We sought to determine if risperidone treatment led 
      to changes in plasma cytokine levels. METHODS: Forty-five subjects from an 
      open-label study of risperidone treatment of children and adolescents with ASD, 
      ages 4-18 years, had an analysis of 27 different cytokines at baseline and after 
      8 weeks of treatment using multiplex assays (Millipore) and read on the Luminex 
      100() platform. We examined changes in each of the cytokine levels in the entire 
      group, and also compared changes in cytokines in responders versus nonresponders. 
      RESULTS: After 8 weeks of risperidone treatment, 2 of the 27 plasma cytokines 
      showed statistically significant decreases in median levels: Eotaxin (p=0.0003) 
      and monocyte chemoattractant protein-1 (MCP-1) (p=0.0024). Six of the 48 subjects 
      met two criteria for responders to risperidone, and the median values of 
      interleukin (IL)-5 were significantly higher (p=0.005) in the overall responder 
      group than in nonresponders. CONCLUSIONS: Two cytokines, eotaxin and MCP-1, which 
      have previously been identified as abnormally elevated in children with autism, 
      decreased during treatment with risperidone. This suggests a possible mechanism 
      of action of risperidone treatment and a balancing of the immune system in 
      affected subjects in this very preliminary study.
FAU - Choi, Jae Eun
AU  - Choi JE
AD  - 1 School of Medicine, University of California , San Diego, California.
FAU - Widjaja, Felicia
AU  - Widjaja F
FAU - Careaga, Milo
AU  - Careaga M
FAU - Bent, Stephen
AU  - Bent S
FAU - Ashwood, Paul
AU  - Ashwood P
FAU - Hendren, Robert L
AU  - Hendren RL
LA  - eng
GR  - P01 ES011269/ES/NIEHS NIH HHS/United States
GR  - R21 HD065269/HD/NICHD NIH HHS/United States
GR  - U54 HD079125/HD/NICHD NIH HHS/United States
GR  - R21MH080026/MH/NIMH NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Cytokines)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/pharmacology/*therapeutic use
MH  - Autistic Disorder/*drug therapy
MH  - Child
MH  - Child, Preschool
MH  - Cytokines/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Risperidone/pharmacology/*therapeutic use
PMC - PMC4268580
EDAT- 2014/05/16 06:00
MHDA- 2015/07/21 06:00
PMCR- 2015/12/01
CRDT- 2014/05/16 06:00
PHST- 2014/05/16 06:00 [entrez]
PHST- 2014/05/16 06:00 [pubmed]
PHST- 2015/07/21 06:00 [medline]
PHST- 2015/12/01 00:00 [pmc-release]
AID - 10.1089/cap.2013.0108 [pii]
AID - 10.1089/cap.2013.0108 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2014 Dec;24(10):586-9. doi: 
      10.1089/cap.2013.0108.